Connect your AI

Omeros OMER Derivative Liabilities (Non-Current)

Derivative Liabilities (Non-Current) at other companies

Spyre Therapeutics, Inc.SYRE

$6.69M-59.4%

Other financials

Income statement

Revenue$9.9M—

Gross profit$29.7M—

Operating income-$40.9M-9.2%

Net income$56.1M+268%

EPS (diluted)-$0.59-20.4%

Balance sheet

Cash & equivalents$1.9M-55.3%

Total debt$13.5M-30.3%

Total equity-$63.3M+70.3%

Total assets$286.2M+21.7%

Cash flow

Operating cash flow-$14.5M+59.5%

CapEx--100%

Free cash flow-$14.5M+59.6%

Valuation

Market cap$775.86M+313%

P/S8.6×—

Profitability

Gross margin98.9%—

Operating margin-181.8%—

Net margin-136.6%—

FCF margin-121.6%—

Returns & leverage

Return on equity86.6%—

Debt / equity0.3×-1.1×

Current ratio3×+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's derivative liabilities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Omeros's derivative liabilities (non-current)?: Omeros (OMER) reported derivative liabilities (non-current) of $84.03M in Q1 2026.